Zoticon BioVentures

Zoticon has invested over $100 million to date in promising phase III therapeutics including two oncology products and a cardiovascular.

HQ location

Bet Shemesh, Israel

Website

Recent deals

Unlock the full power of analytics with a premium account

Track company size and historic growth

Track team composition and strength

Track website visits and app downloads

Tech stackLearn more about the technologies and tools that this company uses.

Tech stack